- Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Cytokinetics
- Cytokinetics' Myqorzo succeeds in landmark cardiomyopathy trial Fierce Pharma
- Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease statnews.com
- Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial FirstWord Pharma
- Cytokinetics stock hits 52-week high after ACACIA-HCM trial qz.com
from "news" - Google News https://ift.tt/BQa41Jy
No comments:
Post a Comment